Integration of circulating tumor DNA profiling in the risk stratification of classical Hodgkin lymphoma in children, adolescents, and young adults
Authors:
Open Access
- 20 April 2026
- journal article
- Published by Wiley in HemaSphere
- Vol. 10 (4)
Abstract
This study aimed to define the potential role of circulating tumor DNA (ctDNA) in children, adolescents, and young adults (CAYA) with classical Hodgkin lymphoma (cHL). This prospective trial was conducted in France between 2019 and 2023 and recruited CAYA patients (≤25 years old) with a new diagnosis of cHL. Patients were treated according to the EuroNet‐PHL‐C2 trial (EudraCT: 2012‐004053‐88), and plasma ctDNA evaluations were performed at diagnosis, after two cycles of chemotherapy, and in case of relapse. Two hundred and seventy‐five patients were included. Median age at diagnosis was 15 years (range 2–22), and 47% of the patients were treated as advanced stages (treatment level 3 [TL‐3]). Using an 18‐gene amplicon‐based next‐generation sequencing (NGS) targeted panel encompassing the most frequently mutated genes in cHL, at least one mutation was detected in 236/275 patients (86%). B‐symptoms, erythrocyte sedimentation rate, and advanced stages were significantly associated with the level of ctDNA at diagnosis. TP53 mutations (19/275, 7%) were strongly associated with inadequate response at early response assessment. XPO1 and IGLL5 mutations were associated with a higher risk of relapse. The presence of detectable ctDNA after two cycles of chemotherapy (10%) was a strong and independent prognostic marker of relapse.Keywords
This publication has 22 references indexed in Scilit:
- Classical Hodgkin lymphomaThe Lancet, 2021
- Targeted genotyping of circulating tumor DNA for classical Hodgkin lymphoma monitoring: a prospective studyHaematologica, 2020
- Risk and Response Adapted Treatment Guidelines for Managing First Relapsed and Refractory Classical Hodgkin Lymphoma in Children and Young People. Recommendations from the EuroNet Pediatric Hodgkin Lymphoma GroupHemaSphere, 2020
- Genotyping circulating tumor DNA of pediatric Hodgkin lymphomaLeukemia, 2019
- Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphomaBlood, 2018
- Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNAScience Translational Medicine, 2016
- PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict OutcomeJournal of Clinical Oncology, 2016
- Kinetics of Circulating Plasma Cell-Free DNA in Paediatric Classical Hodgkin LymphomaJournal of Cancer, 2016
- Molecular Pathogenesis of Hodgkin's Lymphoma: Increasing Evidence of the Importance of the MicroenvironmentJournal of Clinical Oncology, 2011
- THE LASSO METHOD FOR VARIABLE SELECTION IN THE COX MODELStatistics in Medicine, 1997